Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Astria Therapeutics (NASDAQ:ATXS) and maintained a price target of $17.

January 30, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Astria Therapeutics and kept the price target at $17.
The reiteration of an Outperform rating by a reputable analyst like Laura Chico from Wedbush is a positive signal for investors, suggesting confidence in the company's future performance. Maintaining a price target of $17 indicates that the analyst believes the stock has the potential to reach or exceed this level in the short term, which could influence investor sentiment and drive the stock price upward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100